{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:34:02Z","timestamp":1788888842768,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12035-019-01754-y","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T14:42:58Z","timestamp":1567780978000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Downregulation of 14-3-3 Proteins in Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"57","author":[{"given":"Qiang","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvis","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Raymick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotshna","family":"Kanungo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"1754_CR1","first-page":"343","volume-title":"Physiological and biochemical aspects of nervous integration","author":"BW Moore","year":"1967","unstructured":"Moore BW, Perez VJ (1967) Specific acidic proteins of the nervous system. In: Carlson FD (ed) Physiological and biochemical aspects of nervous integration. Prentice-Hall, Englewood Cliffs, pp. 343\u2013359"},{"key":"1754_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1146\/annurev.pharmtox.40.1.617","volume":"40","author":"H Fu","year":"2000","unstructured":"Fu H, Subramanian RR, Masters SC (2000) 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40:617\u2013647. \nhttps:\/\/doi.org\/10.1146\/annurev.pharmtox.40.1.617","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1754_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/nrn1197","volume":"4","author":"D Berg","year":"2003","unstructured":"Berg D, Holzmann C, Riess O (2003) 14-3-3 proteins in the nervous system. Nat Rev Neurosci 4:752\u2013762. \nhttps:\/\/doi.org\/10.1038\/nrn1197","journal-title":"Nat Rev Neurosci"},{"key":"1754_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1590\/S0100-879X2003000400001","volume":"36","author":"M Rosenquist","year":"2003","unstructured":"Rosenquist M (2003) 14-3-3 proteins in apoptosis. Braz J Med Biol Res 36:403\u2013408","journal-title":"Braz J Med Biol Res"},{"key":"1754_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.semcancer.2006.03.005","volume":"16","author":"A Aitken","year":"2006","unstructured":"Aitken A (2006) 14-3-3 proteins: a historic overview. Semin Cancer Biol 16:162\u2013172","journal-title":"Semin Cancer Biol"},{"key":"1754_CR6","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.semcdb.2011.09.008","volume":"22","author":"AK Gardino","year":"2011","unstructured":"Gardino AK, Yaffe MB (2011) 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol 22:688\u2013695. \nhttps:\/\/doi.org\/10.1016\/j.semcdb.2011.09.008","journal-title":"Semin Cell Dev Biol"},{"key":"1754_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/cells1040754","volume":"1","author":"M Pozuelo-Rubio","year":"2012","unstructured":"Pozuelo-Rubio M (2012) 14-3-3 proteins are regulators of autophagy. Cell 1:754\u2013773. \nhttps:\/\/doi.org\/10.3390\/cells1040754","journal-title":"Cell"},{"key":"1754_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.semcdb.2011.08.005","volume":"22","author":"P Steinacker","year":"2011","unstructured":"Steinacker P, Aitken A, Otto M (2011) 14-3-3 proteins in neurodegeneration. Semin Cell Dev Biol 22:696\u2013704. \nhttps:\/\/doi.org\/10.1016\/j.semcdb.2011.08.005","journal-title":"Semin Cell Dev Biol"},{"key":"1754_CR9","doi-asserted-by":"publisher","first-page":"564534","DOI":"10.1155\/2013\/564534","volume":"2013","author":"T Shimada","year":"2013","unstructured":"Shimada T, Fournier AE, Yamagata K (2013) Neuroprotective function of 14-3-3 proteins in neurodegeneration. Biomed Res Int 2013:564534\u2013564511. \nhttps:\/\/doi.org\/10.1155\/2013\/564534","journal-title":"Biomed Res Int"},{"key":"1754_CR10","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1074\/jbc.270.11.5706","volume":"270","author":"A Aitken","year":"1995","unstructured":"Aitken A, Howell S, Jones D, Madrazo J, Patel Y (1995) 14-3-3 alpha and delta are the phosphorylated forms of raf-activating 14-3-3 beta and zeta. In vivo stoichiometric phosphorylation in brain at a Ser-Pro-Glu-Lys MOTIF. J Biol Chem 270:5706\u20135709","journal-title":"J Biol Chem"},{"key":"1754_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1111\/j.1471-4159.1982.tb07927.x","volume":"38","author":"PF Boston","year":"1982","unstructured":"Boston PF, Jackson P, Kynoch PA, Thompson RJ (1982) Purification, properties, and immunohistochemical localisation of human brain 14-3-3 protein. J Neurochem 38:1466\u20131474","journal-title":"J Neurochem"},{"key":"1754_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0304-3940(96)12598-2","volume":"209","author":"R Layfield","year":"1996","unstructured":"Layfield R, Fergusson J, Aitken A, Lowe J, Landon M, Mayer J (1996) Neurofibrillary tangles of Alzheimer\u2019s disease brains contain 14-3-3 proteins. Neurosci Lett 209:57\u201360","journal-title":"Neurosci Lett"},{"key":"1754_CR13","doi-asserted-by":"publisher","first-page":"25247","DOI":"10.1074\/jbc.M003738200","volume":"275","author":"M Hashiguchi","year":"2000","unstructured":"Hashiguchi M, Sobue K, Paudel HK (2000) 14-3-3zeta is an effector of tau protein phosphorylation. J Biol Chem 275:25247\u201325254. \nhttps:\/\/doi.org\/10.1074\/jbc.M003738200","journal-title":"J Biol Chem"},{"key":"1754_CR14","doi-asserted-by":"publisher","first-page":"26105","DOI":"10.1074\/jbc.M308298200","volume":"279","author":"Z Yuan","year":"2004","unstructured":"Yuan Z, Agarwal-Mawal A, Paudel HK (2004) 14-3-3 binds to and mediates phosphorylation of microtubule-associated tau protein by Ser9-phosphorylated glycogen synthase kinase 3beta in the brain. J Biol Chem 279:26105\u201326114. \nhttps:\/\/doi.org\/10.1074\/jbc.M308298200","journal-title":"J Biol Chem"},{"key":"1754_CR15","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1021\/bi400442d","volume":"52","author":"HY Qureshi","year":"2013","unstructured":"Qureshi HY, Li T, MacDonald R, Cho CM, Leclerc N, Paudel HK (2013) Interaction of 14-3-3\u03b6 with microtubule-associated protein tau within Alzheimer\u2019s disease neurofibrillary tangles. Biochemistry 52:6445\u20136455. \nhttps:\/\/doi.org\/10.1021\/bi400442d","journal-title":"Biochemistry"},{"key":"1754_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jnen\/61.3.245","volume":"61","author":"Y Kawamoto","year":"2002","unstructured":"Kawamoto Y, Akiguchi I, Nakamura S, Honjyo Y, Shibasaki H, Budka H (2002) 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J Neuropathol Exp Neurol 61:245\u2013253","journal-title":"J Neuropathol Exp Neurol"},{"key":"1754_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0169-328X(02)00510-7","volume":"108","author":"A Ubl","year":"2002","unstructured":"Ubl A, Berg D, Holzmann C, Kr\u00fcger R, Berger K, Arzberger T, Bornemann A, Riess O (2002) 14-3-3 protein is a component of Lewy bodies in Parkinson\u2019s disease-mutation analysis and association studies of 14-3-3 eta. Brain Res Mol Brain Res 108:33\u201339","journal-title":"Brain Res Mol Brain Res"},{"key":"1754_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/ana.10621","volume":"54","author":"D Berg","year":"2003","unstructured":"Berg D, Riess O, Bornemann A (2003) Specification of 14-3-3 proteins in Lewy bodies. Ann Neurol 54:135. \nhttps:\/\/doi.org\/10.1002\/ana.10621","journal-title":"Ann Neurol"},{"key":"1754_CR19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/nm0602-600","volume":"8","author":"J Xu","year":"2002","unstructured":"Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600\u2013606. \nhttps:\/\/doi.org\/10.1038\/nm0602-600","journal-title":"Nat Med"},{"key":"1754_CR20","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.1093\/hmg\/ddu275","volume":"23","author":"N Plotegher","year":"2014","unstructured":"Plotegher N, Kumar D, Tessari I, Brucale M, Munari F, Tosatto L, Belluzzi E, Greggio E et al (2014) The chaperone-like protein 14-3-3\u03b7 interacts with human \u03b1-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing \u03b1-synuclein cellular toxicity. Hum Mol Genet 23:5615\u20135629. \nhttps:\/\/doi.org\/10.1093\/hmg\/ddu275","journal-title":"Hum Mol Genet"},{"key":"1754_CR21","doi-asserted-by":"publisher","first-page":"32758","DOI":"10.1074\/jbc.M109.027706","volume":"284","author":"\u00d8 Halskau Jr","year":"2009","unstructured":"Halskau \u00d8 Jr, Ying M, Baumann A, Kleppe R, Rodriguez-Larrea D, Alm\u00e5s B, Haavik J, Martinez A (2009) Three-way interaction between 14-3-3 proteins, the N-terminal region of tyrosine hydroxylase, and negatively charged membranes. J Biol Chem 284:32758\u201332769. \nhttps:\/\/doi.org\/10.1074\/jbc.M109.027706","journal-title":"J Biol Chem"},{"key":"1754_CR22","doi-asserted-by":"publisher","first-page":"14011","DOI":"10.1074\/jbc.M901310200","volume":"284","author":"J Wang","year":"2009","unstructured":"Wang J, Lou H, Pedersen CJ, Smith AD, Perez RG (2009) 14-3-3zeta contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria. J Biol Chem 284:14011\u201314019. \nhttps:\/\/doi.org\/10.1074\/jbc.M901310200","journal-title":"J Biol Chem"},{"key":"1754_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.emboj.7600774","volume":"25","author":"S Sato","year":"2006","unstructured":"Sato S, Chiba T, Sakata E, Kato K, Mizuno Y, Hattori N, Tanaka K (2006) 14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J 25:211\u2013221. \nhttps:\/\/doi.org\/10.1038\/sj.emboj.7600774","journal-title":"EMBO J"},{"key":"1754_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/00207459809000653","volume":"95","author":"I Pirim","year":"1998","unstructured":"Pirim I (1998) Ischemic rat brains contain immunoreactivity of 14-3-3 proteins. Int J Neurosci 95:101\u2013106","journal-title":"Int J Neurosci"},{"key":"1754_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0306-4522(01)00492-4","volume":"109","author":"HC Baxter","year":"2002","unstructured":"Baxter HC, Liu WG, Forster JL, Aitken A, Fraser JR (2002) Immunolocalisation of 14-3-3 isoforms in normal and scrapie-infected murine brain. Neuroscience 109:5\u201314","journal-title":"Neuroscience"},{"key":"1754_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0006-8993(02)03487-X","volume":"956","author":"MP van der Brug","year":"2002","unstructured":"van der Brug MP, Goodenough S, Wilce P (2002) Kainic acid induces 14-3-3 zeta expression in distinct regions of rat brain. Brain Res 956:110\u2013115","journal-title":"Brain Res"},{"key":"1754_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.neulet.2003.11.048","volume":"356","author":"CK Schindler","year":"2004","unstructured":"Schindler CK, Shinoda S, Simon RP, Henshall DC (2004) Subcellular distribution of Bcl-2 family proteins and 14-3-3 within the hippocampus during seizure-induced neuronal death in the rat. Neurosci Lett 356:163\u2013166. \nhttps:\/\/doi.org\/10.1016\/j.neulet.2003.11.048","journal-title":"Neurosci Lett"},{"key":"1754_CR28","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1021\/pr060209x","volume":"5","author":"X Hu","year":"2006","unstructured":"Hu X, Rea HC, Wiktorowicz JE, Perez-Polo JR (2006) Proteomic analysis of hypoxia\/ischemia-induced alteration of cortical development and dopamine neurotransmission in neonatal rat. J Proteome Res 5:2396\u20132404. \nhttps:\/\/doi.org\/10.1021\/pr060209x","journal-title":"J Proteome Res"},{"key":"1754_CR29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/01.STR.0000202587.63936.37","volume":"37","author":"Y Kawamoto","year":"2006","unstructured":"Kawamoto Y, Akiguchi I, Tomimoto H, Shirakashi Y, Honjo Y, Budka H (2006) Upregulated expression of 14-3-3 proteins in astrocytes from human cerebrovascular ischemic lesions. Stroke 37:830\u2013835. \nhttps:\/\/doi.org\/10.1161\/01.STR.0000202587.63936.37","journal-title":"Stroke"},{"key":"1754_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1471-4159.2006.04153.x","volume":"99","author":"CK Schindler","year":"2006","unstructured":"Schindler CK, Heverin M, Henshall DC (2006) Isoform- and subcellular fraction-specific differences in hippocampal 14-3-3 levels following experimentally evoked seizures and in human temporal lobe epilepsy. J Neurochem 99:561\u2013569. \nhttps:\/\/doi.org\/10.1111\/j.1471-4159.2006.04153.x","journal-title":"J Neurochem"},{"key":"1754_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2015.02.032","volume":"79","author":"SR Slone","year":"2015","unstructured":"Slone SR, Lavalley N, McFerrin M, Wang B, Yacoubian TA (2015) Increased 14-3-3 phosphorylation observed in Parkinson\u2019s disease reduces neuroprotective potential of 14-3-3 proteins. Neurobiol Dis 79:1\u201313. \nhttps:\/\/doi.org\/10.1016\/j.nbd.2015.02.032","journal-title":"Neurobiol Dis"},{"key":"1754_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12035-017-0724-y","volume":"55","author":"D Smani","year":"2018","unstructured":"Smani D, Sarkar S, Raymick J, Kanungo J, Paule MG, Gu Q (2018) Down-regulation of 14-3-3 proteins in a kainic acid-induced neurotoxicity model. Mol Neurobiol 55:122\u2013129. \nhttps:\/\/doi.org\/10.1007\/s12035-017-0724-y","journal-title":"Mol Neurobiol"},{"key":"1754_CR33","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1124\/mol.60.6.1325","volume":"60","author":"SC Masters","year":"2001","unstructured":"Masters SC, Yang H, Datta SR, Greenberg ME, Fu H (2001) 14-3-3 inhibits bad-induced cell death through interaction with serine-136. Mol Pharmacol 60:1325\u20131331","journal-title":"Mol Pharmacol"},{"key":"1754_CR34","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1471-4159.2008.05447.x","volume":"106","author":"N Murphy","year":"2008","unstructured":"Murphy N, Bonner HP, Ward MW, Murphy BM, Prehn JH, Henshall DC (2008) Depletion of 14-3-3 zeta elicits endoplasmic reticulum stress and cell death, and increases vulnerability to kainate-induced injury in mouse hippocampal cultures. J Neurochem 106:978\u2013988. \nhttps:\/\/doi.org\/10.1111\/j.1471-4159.2008.05447.x","journal-title":"J Neurochem"},{"key":"1754_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2009.4","volume":"1","author":"TA Yacoubian","year":"2010","unstructured":"Yacoubian TA, Slone SR, Harrington AJ, Hamamichi S, Schieltz JM, Caldwell KA, Caldwell GA, Standaert DG (2010) Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson\u2019s disease. Cell Death Dis 1:e2. \nhttps:\/\/doi.org\/10.1038\/cddis.2009.4","journal-title":"Cell Death Dis"},{"key":"1754_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021720","volume":"6","author":"SR Slone","year":"2011","unstructured":"Slone SR, Lesort M, Yacoubian TA (2011) 14-3-3theta protects against neurotoxicity in a cellular Parkinson\u2019s disease model through inhibition of the apoptotic factor Bax. PLoS One 6:e21720. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0021720","journal-title":"PLoS One"},{"key":"1754_CR37","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/CIRCULATIONAHA.108.812537","volume":"119","author":"JS Wu","year":"2009","unstructured":"Wu JS, Cheung WM, Tsai YS, Chen YT, Fong WH, Tsai HD, Chen YC, Liou JY et al (2009) Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 119:1124\u20131134. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.812537","journal-title":"Circulation"},{"key":"1754_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093334","volume":"9","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Bu Q, Liu X, Hu W, Wang Y (2014) Neuroprotective effect of TAT-14-3-3\u03b5 fusion protein against cerebral ischemia\/reperfusion injury in rats. PLoS One 9:e93334. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0093334","journal-title":"PLoS One"},{"key":"1754_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neuroscience.2015.08.042","volume":"307","author":"H Ding","year":"2015","unstructured":"Ding H, Underwood R, Lavalley N, Yacoubian TA (2015) 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3\u03b8 overexpression promotes recovery in the MPTP mouse model of Parkinson's disease. Neuroscience 307:73\u201382. \nhttps:\/\/doi.org\/10.1016\/j.neuroscience.2015.08.042","journal-title":"Neuroscience"},{"key":"1754_CR40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1474-4422(16)00067-3","volume":"15","author":"CM Mazure","year":"2016","unstructured":"Mazure CM, Swendsen J (2016) Sex differences in Alzheimer\u2019s disease and other dementias. Lancet Neurol 15:451\u2013452. \nhttps:\/\/doi.org\/10.1016\/S1474-4422(16)00067-3","journal-title":"Lancet Neurol"},{"key":"1754_CR41","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.brainres.2017.11.014","volume":"1678","author":"E Lu","year":"2018","unstructured":"Lu E, Sarkar S, Raymick J, Paule MG, Gu Q (2018) Decreased Mcl-1 protein level in the striatum of a Parkinson\u2019s disease animal model. Brain Res 1678:432\u2013439. \nhttps:\/\/doi.org\/10.1016\/j.brainres.2017.11.014","journal-title":"Brain Res"},{"key":"1754_CR42","first-page":"323","volume":"57","author":"M Fountoulakis","year":"1999","unstructured":"Fountoulakis M, Cairns N, Lubec G (1999) Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer\u2019s disease and Down syndrome. J Neural Transm Suppl 57:323\u2013335","journal-title":"J Neural Transm Suppl"},{"key":"1754_CR43","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1530-0277.2011.01436.x","volume":"35","author":"RK MacKay","year":"2011","unstructured":"MacKay RK, Colson NJ, Dodd PR, Lewohl JM (2011) Differential expression of 14-3-3 isoforms in human alcoholic brain. Alcohol Clin Exp Res 35:1041\u20131049. \nhttps:\/\/doi.org\/10.1111\/j.1530-0277.2011.01436.x","journal-title":"Alcohol Clin Exp Res"},{"key":"1754_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0169-328X(94)90285-2","volume":"25","author":"M Watanabe","year":"1994","unstructured":"Watanabe M, Isobe T, Ichimura T, Kuwano R, Takahashi Y, Kondo H, Inoue Y (1994) Molecular cloning of rat cDNAs for the zeta and theta subtypes of 14-3-3 protein and differential distributions of their mRNAs in the brain. Brain Res Mol Brain Res 25:113\u2013121","journal-title":"Brain Res Mol Brain Res"},{"key":"1754_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2011.06.036","volume":"1410","author":"T Umahara","year":"2011","unstructured":"Umahara T, Uchihara T, Nakamura A, Iwamoto T (2011) Differential expression of 14-3-3 protein isoforms in developing rat hippocampus, cortex, rostral migratory stream, olfactory bulb, and white matter. Brain Res 1410:1\u201311. \nhttps:\/\/doi.org\/10.1016\/j.brainres.2011.06.036","journal-title":"Brain Res"},{"key":"1754_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054491","volume":"8","author":"GP Brennan","year":"2013","unstructured":"Brennan GP, Jimenez-Mateos EM, McKiernan RC, Engel T, Tzivion G, Henshall DC (2013) Transgenic overexpression of 14-3-3 zeta protects hippocampus against endoplasmic reticulum stress and status epilepticus in vivo. PLoS One 8:e54491. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0054491","journal-title":"PLoS One"},{"key":"1754_CR47","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1074\/jbc.M207880200","volume":"278","author":"M Nomura","year":"2003","unstructured":"Nomura M, Shimizu S, Sugiyama T, Narita M, Ito T, Matsuda H, Tsujimoto Y (2003) 14-3-3 interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem 278:2058\u20132065. \nhttps:\/\/doi.org\/10.1074\/jbc.M207880200","journal-title":"J Biol Chem"},{"key":"1754_CR48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11068-008-9018-7","volume":"35","author":"JJ Lundquist","year":"2006","unstructured":"Lundquist JJ, Dudek SM (2006) Differential activation of extracellular signal-regulated kinase 1 and a related complex in neuronal nuclei. Brain Cell Biol 35:267\u2013281. \nhttps:\/\/doi.org\/10.1007\/s11068-008-9018-7","journal-title":"Brain Cell Biol"},{"key":"1754_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0076-6879(86)34078-3","volume":"134","author":"RB Vallee","year":"1986","unstructured":"Vallee RB (1986) Reversible assembly purification of microtubules without assembly-promoting agents and further purification of tubulin, microtubule-associated proteins, and MAP fragments. Methods Enzymol 134:89\u2013104","journal-title":"Methods Enzymol"},{"key":"1754_CR50","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/0166-2236(93)90078-Z","volume":"16","author":"M Goedert","year":"1993","unstructured":"Goedert M (1993) Tau protein and the neurofibrillary pathology of Alzheimer\u2019s disease. Trends Neurosci 16:460\u2013465","journal-title":"Trends Neurosci"},{"key":"1754_CR51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bbrc.2009.03.107","volume":"383","author":"G Sadik","year":"2009","unstructured":"Sadik G, Tanaka T, Kato K, Yanagi K, Kudo T, Takeda M (2009) Differential interaction and aggregation of 3-repeat and 4-repeat tau isoforms with 14-3-3zeta protein. Biochem Biophys Res Commun 383:37\u201341. \nhttps:\/\/doi.org\/10.1016\/j.bbrc.2009.03.107","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-01754-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-019-01754-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-01754-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T23:09:29Z","timestamp":1599174569000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-019-01754-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1754"],"URL":"https:\/\/doi.org\/10.1007\/s12035-019-01754-y","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"29 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The information in these materials is not a formal dissemination of information by FDA and does not represent agency position or policy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}